-
Document de presse | 2015.12.21
The mechanism of an AIDS vaccine candidate filmed in vivo
Using innovative technology, scientists from the Institut Pasteur and Inserm have filmed in vivo the process by which an AIDS vaccine candidate, developed by the French Vaccine Research Institute and the ANRS, triggers the immune response. This previously unseen footage clearly shows how the vaccine recruits the immune cells needed to destroy infected cells. These results, published in the...
-
Document de presse | 2009.01.14
Vaccine against shigellosis (bacillary dysentery):a promising clinical trial
The results of a clinical trial aimed to assess the effectiveness of an oral vaccine against Shigella dysenteriae serotype 1, the bacterium responsible for the epidemic form of Shigellosis or bacillary dysentery, a severe and often fatal diarrheic disease, have just been published in the journal Vaccine. Developed by a team from the Institut Pasteur and Inserm, this vaccine proved to be well...
-
Article | 2020.06.22
rBCG vaccine secreting SARS-CoV-2 antigens
Aim: Mycobacterium bovis BCG is a live attenuated vaccine that is used since almost 100 years for the vaccination against tuberculosis, with a solid safety record in billions of immunocompetent individuals. The aim of the project is to construct recombinant BCG strains that express viral protein(s) of the SARS-CoV-2 virus in fusion with the 6 kD early secreted antigenic target (ESAT-6...
-
Document de presse | 2023.03.07
A New Milestone in the Development of an Effective Allergic Asthma Vaccine
To combat allergic asthma, which affects millions of people worldwide, scientists from Inserm, CNRS and Université Toulouse III-Paul Sabatier at the Infinity laboratory[1], Institut Pasteur and French company NEOVACS are developing and testing a new vaccine. In their previous study, the teams had shown it to be effective in producing antibodies capable of neutralizing human immune proteins that...
-
News | 2023.01.06
Development of a pentavalent vaccine against New World arenaviruses
An Institut Pasteur team has successfully developed a pentavalent vaccine against the five pathogenic arenaviruses circulating in South America and tested it in a primate model. Each of the viruses has a low incidence but a very high mortality rate, so combining them in a single vaccine would help facilitate vaccine development and ensure that the population can be protected as soon as possible...
-
Document de presse | 2018.06.13
Yellow fever: a new method for testing vaccine safety
Development of a cellular test to verify the safety of live vaccines, such as the yellow fever vaccine, without the need to use animal testing.Scientists from the Institut Pasteur, the CNRS and Sanofi Pasteur have recently developed a novel alternative method to animal testing that can be used to verify the safety of vaccines such as the yellow fever vaccine. This original approach is based on...
-
News | 2022.04.28
Understanding how the whooping cough bacterium has evolved in response to vaccination
In a recent study stemming from an international partnership involving several Institut Pasteur scientists, work was carried out on modeling the spatial dynamics and evolution of Bordetella pertussis, the bacterium responsible for whooping cough.
-
Document de presse | 2007.11.12
Malaria: the importance of the MSP3 candidate vaccine has been confirmed
A vast immunoepidemiological study, published in PLoS Medicine, has just confirmed the importance of a candidate vaccine against malaria, named MSP3, under development at the Institut Pasteur. The study shows that the antibodies directed against this molecule, produced by the exposed subjects, are closely associated with protection against the disease, including among young children—unlike...
-
News | 2023.07.10
HIV-AIDS: a virus master of evasion
Developing effective therapeutic vaccines requires knowing how to chemically recognize microbes, as well as exposing them to treatment. Able to mutate very quickly and to camouflage itself inside the cells it infects, the AIDS virus (or HIV) constitutes a challenge for researchers.
-
Document de presse | 2025.05.23
Launch of the European Vaccines Hub for Pandemic Readiness, a new European public-private partnership for public health-relevant vaccine development
The Health Emergency Preparedness and Response Authority (HERA) of the European Commission, through the European Health and Digital Executive Agency (HaDEA) supports the establishment of the “European Vaccines Hub (EVH) for Pandemic Readiness”, a pan-European center dedicated to advancing public-health–relevant vaccine development. The Grant Agreement has been signed today, marking a...